ERC Projects

4. "ALINA"

From January 2027 until June 2028, we will be funded by an ERC-Proof-of-Concept grant "ALINA" to develop and validate an integrated machine learning– and molecular dynamics–based platform for predictive mRNA-loaded lipid nanoparticle (LNP) formulation under grant number ERC-2026-PoC1-101334799. The project logically builds upon our ERC Consolidator Grant project “RatInhalRNA” with the aim of refining, translating, and exploiting our findings in RNA nanoformulation, computational prediction, and extrahepatic delivery. 

The project has the clear goal of assessing the commercial positioning of a platform technology for ML-MD-guided mRNA-LNP formulation design and of refining existing machine-learning models, molecular-dynamics challenge frameworks, and multimodal datasets to overcome current bottlenecks in RNA therapeutics.

Project-related publications:

 

3. "RatInhalRNA"

Since 2023, we have been funded by an ERC Consolidator Grant "RatInhalRNA" to develop inhalable RNA nanocarriers by machine learning and molecular dynamics simulations under grant number ERC-2022-COG-101088587. The project consolidates previous work from our ERC-StG project "Novel Asthma Therapy" with the aim of more rationally designing polymer nanocarriers for RNA by computational and limited experimental work. (Figure credits to Dr. Ben Winkeljann)

The project has a clear aim of reducing wet lab efforts by establishing machine learning algorithms based on experimental data for prediciting improved nanocarriers in a use case of antiviral siRNA against respiratory virus infections.

Project-related publications:

 

2. "RNhale"

From July 2022 until December 2023, we were funded by an ERC-Proof-of-Concept grant "RNhale" to develop dry powder formulations of RNA-loaded nanoparticles by spray drying under grant number ERC-2022-PoC1-101069308. The project logically builds upon our ERC-StG project "Novel Asthma Therapy" with the aim of refining, translating and exploiting our findings. (Figure credits to Dr. Ben Winkeljann)

The project had a clear aim of assessing the commercial positioning of a platform technology for spray-drying RNA and of refining existing protocols for spray-drying RNA NPs made with diverse RNA NPs to overcome current challenges of storage and transport conditions as well as delivery beyond the liver and has resulted in the founding and spin-off of RNhale GmbH.

Project-related publications:

 

 

1. "Novel Asthma Therapy"

 

From October 2015 until December 2021, we developed dry powder platform technologies for targeted pulmonary siRNA delivery to activated T cells in the lung under the ERC Starting Grant ERC-2014-StG – 637830 "Novel Asthma Therapy".
 

The project had a clear aim of advancing pulmonary nanomedicine as novel asthma therapy specifically and RNA delivery in general.

Project-related publications: